The article has been corrected to say that BioChain is supplying ArcherDx with tumor samples.
NEW YORK (GenomeWeb) – ArcherDx today announced a deal under which BioChain will supply it with multiple types of formalin-fixed, paraffin-embedded tumor samples.
The samples, which include non-small cell lung cancer samples, will be screened for cancer fusions, copy number variations, SNPs, and insertions and deletions using the ArcherDx VariantPlex and FusionPlex solid tumor assays, ArcherDx said. BioChain will make the FFPE tumor samples available to researchers under the CancerSeq Plus brand.
Financial and other terms of the deal were not disclosed.
"By combining Archer's [next-generation sequencing] expertise with BioChain's large tissue repository and market presence, we've created genotyped tissue products that will be a welcome addition for many laboratories," ArcherDx Director of Marketing Jason Amsbaugh said in a statement.
Boulder, Colorado-based ArcherDx develops kits and software solutions for next-generation sequencing. BioChain is based in Newark, California and supplies biospecimen and life science reagents.